(VCYT) Veracyte - Overview

Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 2.563m USD | Total Return: 13.1% in 12m

Cancer Tests, Genomic Analysis, Diagnostics
Total Rating 32
Safety 43
Buy Signal -0.62
Diagnostics & Research
Industry Rotation: +10.3
Market Cap: 2.56B
Avg Turnover: 26.7M USD
ATR: 4.56%
Peers RS (IBD): 13.3
Risk 5d forecast
Volatility50.1%
Rel. Tail Risk-10.4%
Reward TTM
Sharpe Ratio0.37
Alpha-20.96
Character TTM
Beta0.951
Beta Downside0.435
Drawdowns 3y
Max DD50.09%
CAGR/Max DD0.31
EPS (Earnings per Share) EPS (Earnings per Share) of VCYT over the last years for every Quarter: "2021-03": -0.11, "2021-06": -0.13, "2021-09": -0.2, "2021-12": -0.15, "2022-03": -0.2, "2022-06": -0.13, "2022-09": -0.12, "2022-12": -0.05, "2023-03": -0.11, "2023-06": -0.12, "2023-09": -0.41, "2023-12": -0.39, "2024-03": -0.02, "2024-06": 0.07, "2024-09": 0.19, "2024-12": 0.36, "2025-03": 0.31, "2025-06": 0.44, "2025-09": 0.51, "2025-12": 0.53, "2026-03": 0,
EPS CAGR: 10.20%
EPS Trend: 71.6%
Last SUE: -2.46
Qual. Beats: 0
Revenue Revenue of VCYT over the last years for every Quarter: 2021-03: 36.703, 2021-06: 55.105, 2021-09: 60.37, 2021-12: 67.336, 2022-03: 67.783, 2022-06: 72.864, 2022-09: 75.592, 2022-12: 80.297, 2023-03: 82.422, 2023-06: 90.322, 2023-09: 90.108, 2023-12: 98.199, 2024-03: 96.844, 2024-06: 114.428, 2024-09: 115.86, 2024-12: 118.632, 2025-03: 114.473, 2025-06: 130.164, 2025-09: 131.872, 2025-12: 140.636, 2026-03: null,
Rev. CAGR: 21.49%
Rev. Trend: 98.9%
Last SUE: 1.36
Qual. Beats: 4

Warnings

Altman Z'' -2.77 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: VCYT Veracyte

Veracyte, Inc. is a South San Francisco-based diagnostics company specializing in genomic testing for various cancers, including thyroid, prostate, bladder, breast, and lung. The company utilizes advanced genomic sequencing technology to provide clinical insights that help physicians avoid unnecessary invasive procedures and optimize treatment plans.

Operating within the molecular diagnostics sector, Veracyte utilizes a high-complexity laboratory service model where patient samples are analyzed to identify specific genetic signatures. This sector is characterized by high research and development costs and a reliance on reimbursement approvals from both private insurers and government health programs.

The company continues to expand its portfolio through the development of the nCounter analysis system, aiming to further integrate its diagnostic tools into global clinical workflows. Investors looking for deeper insights into the companys valuation and growth metrics can find comprehensive data on ValueRay. Veracyte originally operated under the name Calderome, Inc. before rebranding in 2008 and currently maintains an international presence in the biotechnology market.

Headlines to Watch Out For
  • Genomic test adoption drives revenue growth
  • Reimbursement policies impact diagnostic test profitability
  • Clinical trial results influence product pipeline
  • Regulatory approvals affect market access
  • Competition in cancer diagnostics pressures pricing
Piotroski VR‑10 (Strict) 6.5
Net Income: 66.4m TTM > 0 and > 6% of Revenue
FCF/TA: 0.09 > 0.02 and ΔFCF/TA 4.06 > 1.0
NWC/Revenue: 82.85% < 20% (prev 65.87%; Δ 16.97% < -1%)
CFO/TA 0.10 > 3% & CFO 136.3m > Net Income 66.4m
Net Debt (-373.2m) to EBITDA (83.4m): -4.48 < 3
Current Ratio: 8.15 > 1.5 & < 3
Outstanding Shares: last quarter (81.4m) vs 12m ago 1.85% < -2%
Gross Margin: 70.63% > 18% (prev 0.67%; Δ 7.00k% > 0.5%)
Asset Turnover: 38.22% > 50% (prev 34.29%; Δ 3.93% > 0%)
Interest Coverage Ratio: 61.9k > 6 (EBITDA TTM 83.4m / Interest Expense TTM 1.00k)
Altman Z'' -2.77
A: 0.30 (Total Current Assets 488.4m - Total Current Liabilities 59.9m) / Total Assets 1.41b
B: -0.27 (Retained Earnings -377.6m / Total Assets 1.41b)
C: 0.05 (EBIT TTM 61.9m / Avg Total Assets 1.35b)
D: -4.00 (Book Value of Equity -385.8m / Total Liabilities 96.4m)
Altman-Z'' Score: -2.77 = D
Beneish M -3.20
DSRI: 0.83 (Receivables 44.7m/46.5m, Revenue 517.1m/445.8m)
GMI: 0.95 (GM 70.63% / 66.88%)
AQI: 0.93 (AQ_t 0.61 / AQ_t-1 0.66)
SGI: 1.16 (Revenue 517.1m / 445.8m)
TATA: -0.05 (NI 66.4m - CFO 136.3m) / TA 1.41b)
Beneish M-Score: -3.20 (Cap -4..+1) = AA
What is the price of VCYT shares? As of April 09, 2026, the stock is trading at USD 32.67 with a total of 793,307 shares traded.
Over the past week, the price has changed by +0.83%, over one month by -2.10%, over three months by -25.00% and over the past year by +13.12%.
Is VCYT a buy, sell or hold? Veracyte has received a consensus analysts rating of 4.27. Therefore, it is recommended to buy VCYT.
  • StrongBuy: 7
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 1
What are the forecasts/targets for the VCYT price?
Analysts Target Price 47 43.9%
Veracyte (VCYT) - Fundamental Data Overview as of 05 April 2026
P/E Trailing = 39.3293
P/E Forward = 22.5225
P/S = 4.9552
P/B = 1.9659
Revenue TTM = 517.1m USD
EBIT TTM = 61.9m USD
EBITDA TTM = 83.4m USD
Long Term Debt = 39.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.05m USD (from shortTermDebt, last quarter)
Debt = 39.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -373.2m USD (recalculated: Debt 39.7m - CCE 412.9m)
Enterprise Value = 2.19b USD (2.56b + Debt 39.7m - CCE 412.9m)
Interest Coverage Ratio = 61.9k (Ebit TTM 61.9m / Interest Expense TTM 1.00k)
EV/FCF = 17.36x (Enterprise Value 2.19b / FCF TTM 126.1m)
FCF Yield = 5.76% (FCF TTM 126.1m / Enterprise Value 2.19b)
FCF Margin = 24.38% (FCF TTM 126.1m / Revenue TTM 517.1m)
Net Margin = 12.83% (Net Income TTM 66.4m / Revenue TTM 517.1m)
Gross Margin = 70.63% ((Revenue TTM 517.1m - Cost of Revenue TTM 151.9m) / Revenue TTM)
Gross Margin QoQ = 74.43% (prev 69.22%)
Tobins Q-Ratio = 1.56 (Enterprise Value 2.19b / Total Assets 1.41b)
Interest Expense / Debt = 0.00% (Interest Expense 1.00k / Debt 39.7m)
Taxrate = 2.71% (1.85m / 68.2m)
NOPAT = 60.3m (EBIT 61.9m * (1 - 2.71%))
Current Ratio = 8.15 (Total Current Assets 488.4m / Total Current Liabilities 59.9m)
Debt / Equity = 0.03 (Debt 39.7m / totalStockholderEquity, last quarter 1.31b)
Debt / EBITDA = -4.48 (Net Debt -373.2m / EBITDA 83.4m)
Debt / FCF = -2.96 (Net Debt -373.2m / FCF TTM 126.1m)
Total Stockholder Equity = 1.25b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.90% (Net Income 66.4m / Total Assets 1.41b)
RoE = 5.33% (Net Income TTM 66.4m / Total Stockholder Equity 1.25b)
RoCE = 4.82% (EBIT 61.9m / Capital Employed (Equity 1.25b + L.T.Debt 39.7m))
RoIC = 4.84% (NOPAT 60.3m / Invested Capital 1.25b)
WACC = 9.19% (E(2.56b)/V(2.60b) * Re(9.33%) + D(39.7m)/V(2.60b) * Rd(0.00%) * (1-Tc(0.03)))
Discount Rate = 9.33% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.51%
[DCF] Terminal Value 77.81% ; FCFF base≈101.2m ; Y1≈124.8m ; Y5≈213.0m
[DCF] Fair Price = 41.64 (EV 2.94b - Net Debt -373.2m = Equity 3.31b / Shares 79.5m; r=9.19% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 71.63 | EPS CAGR: 10.20% | SUE: -2.46 | # QB: 0
Revenue Correlation: 98.86 | Revenue CAGR: 21.49% | SUE: 1.36 | # QB: 4
EPS next Quarter (2026-06-30): EPS=0.42 | Chg7d=+0.000 | Chg30d=+0.005 | Revisions Net=+7 | Analysts=11
EPS current Year (2026-12-31): EPS=1.65 | Chg7d=-0.002 | Chg30d=-0.008 | Revisions Net=+6 | Growth EPS=-7.4% | Growth Revenue=+11.5%
EPS next Year (2027-12-31): EPS=1.77 | Chg7d=+0.000 | Chg30d=+0.016 | Revisions Net=+4 | Growth EPS=+7.5% | Growth Revenue=+12.3%
[Analyst] Revisions Ratio: +1.00 (7 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.8% (Discount Rate 9.3% - Earnings Yield 2.5%)
[Growth] Growth Spread = +3.8% (Analyst 10.6% - Implied 6.8%)
External Resources
Dataroma Stockcircle